Learning Objectives:
1.Understand how the pathophysiology and genetics of CML led to the development of target therapies
2.Learn the patient outcomes from treatment for CML with BCR-ABL1 tyrosine kinase inhibitors
Session date:
06/18/2024 - 12:00pm to 1:00pm CDT
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Richard Larson, MD